Protecting intubated patients from the threat of antimicrobial resistant infections with monoclonal antibodies

Baker, Stephen; Kellam, Paul; Krishna, Aishwarya; Reece, Stephen T.

doi:10.1016/s2666-5247(20)30126-9

Cited by 4 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the heterogeneity amongst the LcrV proteins from different isolates [ 30 , 75 ], the level of protection afforded by mAb 7.3 may drastically diminish if that specific epitope is altered; however, greater epitope coverage by polyclonal antibodies derived from Tc bovines may mitigate those possibilities. Additionally, novel antibody-based medical countermeasures will become increasingly more important strategies to combat anti-microbial resistance [ 76 , 77 , 78 ]. Drug-resistant isolates of Y. pestis have been isolated in several regions of Madagascar during relatively recent plague outbreaks and multi-drug resistant isolates continue to be of the utmost concern in both public health and biodefense arenas [ 79 , 80 ].…”

Section: Discussionmentioning

confidence: 99%

Polyclonal Antibodies Derived from Transchromosomic Bovines Vaccinated with the Recombinant F1-V Vaccine Increase Bacterial Opsonization In Vitro and Protect Mice from Pneumonic Plague

Biryukov

Dankmeyer

et al. 2023

Antibodies

View full text Add to dashboard Cite

Plague is an ancient disease that continues to be of concern to both the public health and biodefense research communities. Pneumonic plague is caused by hematogenous spread of Yersinia pestis bacteria from a ruptured bubo to the lungs or by directly inhaling aerosolized bacteria. The fatality rate associated with pneumonic plague is significant unless effective antibiotic therapy is initiated soon after an early and accurate diagnosis is made. As with all bacterial pathogens, drug resistance is a primary concern when developing strategies to combat these Yersinia pestis infections in the future. While there has been significant progress in vaccine development, no FDA-approved vaccine strategy exists; thus, other medical countermeasures are needed. Antibody treatment has been shown to be effective in animal models of plague. We produced fully human polyclonal antibodies in transchromosomic bovines vaccinated with the recombinant F1-V plague vaccine. The resulting human antibodies opsonized Y. pestis bacteria in the presence of RAW264.7 cells and afforded significant protection to BALB/c mice after exposure to aerosolized Y. pestis. These data demonstrate the utility of this technology to produce large quantities of non-immunogenic anti-plague human antibodies to prevent or possibly treat pneumonic plague in human.

show abstract

Section: Discussionmentioning

confidence: 99%

Polyclonal Antibodies Derived from Transchromosomic Bovines Vaccinated with the Recombinant F1-V Vaccine Increase Bacterial Opsonization In Vitro and Protect Mice from Pneumonic Plague

Biryukov

Dankmeyer

et al. 2023

Antibodies

View full text Add to dashboard Cite

show abstract

“…Within intensive care unit (ICU) settings, A. baumannii is one of the most common causative agents of VAP and is associated frequently with poor patient outcomes ( 2 , 3 ). During the ongoing COVID-19 pandemic, challenges faced by health care professionals have been further exacerbated by multidrug-resistant (MDR) and extensively drug resistant (XDR) A. baumannii outbreaks ( 4 – 7 ). Recent reports suggest that up to 80% of ICU-admitted COVID-19 patients required invasive mechanical ventilation ( 8 ).…”

Section: Introductionmentioning

confidence: 99%

Rescuing Tetracycline Class Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii Pulmonary Infection

Oliveira

Forde

Phan

et al. 2022

mBio

View full text Add to dashboard Cite

Within intensive care unit settings, multidrug-resistant (MDR) Acinetobacter baumannii is a major cause of ventilator-associated pneumonia, and hospital-associated outbreaks are becoming increasingly widespread. Antibiotic treatment of A. baumannii infection is often compromised by MDR strains resistant to last-resort β-lactam (e.g., carbapenems), polymyxin, and tetracycline class antibiotics.

show abstract

Exploiting human immune repertoire transgenic mice for protective monoclonal antibodies against antimicrobial resistant Acinetobacter baumannii

Baker,

Krishna,

Higham

et al. 2024

Nat Commun

View full text Add to dashboard Cite

Protecting intubated patients from the threat of antimicrobial resistant infections with monoclonal antibodies

Cited by 4 publications

References 5 publications

Polyclonal Antibodies Derived from Transchromosomic Bovines Vaccinated with the Recombinant F1-V Vaccine Increase Bacterial Opsonization In Vitro and Protect Mice from Pneumonic Plague

Polyclonal Antibodies Derived from Transchromosomic Bovines Vaccinated with the Recombinant F1-V Vaccine Increase Bacterial Opsonization In Vitro and Protect Mice from Pneumonic Plague

Rescuing Tetracycline Class Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii Pulmonary Infection

Exploiting human immune repertoire transgenic mice for protective monoclonal antibodies against antimicrobial resistant Acinetobacter baumannii

Contact Info

Product

Resources

About